Glioblastoma Research
Clinical research in glioblastoma focuses on newly diagnosed disease and treatment combinations involving temozolomide and radiotherapy, with attention to disease control and treatment tolerance in aggressive brain tumours.
- Temozolomide
- Radiotherapy
- Newly diagnosed glioblastoma
The sponsor’s activity in this area is centred on therapeutic strategies for high-grade glioma management.
IDH1/2-mutated astrocytoma
Research in IDH1/2-mutated astrocytoma addresses recurrent disease, with emphasis on targeted treatment approaches for tumours carrying ATRX and p53 mutations.
- Recurrent astrocytoma
- IDH mutation
- ATRX mutation
These studies reflect a focused interest in molecularly defined neuro-oncology populations.
Targeted therapy in recurrent disease
The sponsor supports investigation of tuvusertib in recurrent astrocytoma, with clinical interest in disease progression, magnetic resonance imaging assessment, and outcomes aligned to RANO criteria.
- Tuvusertib
- Progression-free survival
- MRI-based assessment
This area highlights work in precision-directed treatment for molecularly selected brain tumours.
Neuro-oncology clinical development
Across its active studies, the sponsor is engaged in central nervous system oncology research involving recurrent and newly diagnosed tumour settings, with collaboration across multiple research sites in Spain.
- Brain tumour oncology
- Multicentre collaboration
- Clinical research in Spain
Its trial portfolio is concentrated on therapeutic questions in malignant glioma and genetically characterised astrocytic tumours.
